ApoA-1 Milano
From Wikipedia, the free encyclopedia
A naturally-occurring mutated strain of the apoA-1 protein found in human HDL. First identified by Cesare Sirtori in Milan, it has been shown to significantly reduce arterial plaque.
Discovered by accident, the mutation was found to be present in about 3.5% of a tiny village called Limone sul Garda in northern Italy. It has been traced to a mutation in a single man living in the village in the 1700s.
Due to its enormous apparent efficacy, some have speculated that development of synthetic apoA-1 Milano may be a key factor in eradicating coronary heart disease.
No drugs are currently commercially available based on apoA-1 Milano. Rights to apoA-1 Milano were acquired in 2003 by Pfizer.
[edit] External links
- Time.com: Drano for the Heart
- USATODAY.com: 'Next frontier' in heart disease: Undoing it
- About.com: Synthetic HDL shrinks coronary artery plaques
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
